Sacrococcygeal teratoma Cancer
Conditions
Interventions
This observational study looks at tumour histology at initial resection and the time between birth and surgery. Furthermore, risk factors associated with recurrence will be analysed.
Collected data
Sponsors
Foundation KiKa
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: All patients with SCT treated by each participating centre during a set time
Exclusion criteria
Exclusion criteria: Patients treated for sacrococcygeal teratoma before 1980
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The following primary outcomes are measured using patient medical records at a one-time point: 1. Malignant transformation of the initial tumour confirmed by pathology. 2. Risk factors associated with sacrococcygeal teratoma recurrence defined as relapse of the tumour at least three months after initial resection. | — |
Secondary
| Measure | Time frame |
|---|---|
| The following secondary outcomes are measured using patient medical records at a one-time point: 1. Treatment modality for sacrococcygeal teratoma patients from different income countries 2. Outcomes of treatment for sacrococcygeal teratoma patients from different income countries | — |
Countries
Afghanistan, Argentina, Austria, Bangladesh, Belarus, Belgium, Brazil, Bulgaria, Cameroon, Canada, Chile, China, Côte d'Ivoire, Croatia, Czech Republic, Denmark, Egypt, Estonia, Ethiopia, Finland, France, Germany, Ghana, Greece, Hong Kong, Hungary, India, Indonesia, Iran, Iraq, Ireland, Israel, Italy, Japan, Korea, South, Latvia, Lithuania, Malaysia, Mexico, Montenegro, Morocco, Netherlands, Nigeria, North Macedonia, Norway, Pakistan, Philippines, Poland, Portugal, Romania, Russian Federation, Serbia, Singapore, Slovakia, Slovenia, Spain, Sri Lanka, Sweden, Syria, Taiwan, Thailand, Tunisia, Türkiye, Ukraine, United Kingdom, United States of America, Zambia
Contacts
Public ContactLieke van Heurn
Outcome results
None listed